Weekly Vinorelbine and Oral Capecitabine as Treatment for Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions
Breast Neoplasm
Interventions
DRUG

Vinorelbine

20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.

DRUG

Capecitabine

825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.

Trial Locations (1)

98109-1023

University of Washington; Seattle Cancer Care Alliance, Seattle

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Pfizer

INDUSTRY

lead

University of Washington

OTHER